These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1729729)

  • 1. The absorption characteristics of six sustained-release theophylline preparations.
    Sommers DK; van Wyk M; Meyer EC; Snyman JR; Moncrieff J
    S Afr Med J; 1992 Jan; 81(1):20-2. PubMed ID: 1729729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relation of product formulation to absorption of oral theophylline.
    Weinberger M; Hendeles L; Bighley L
    N Engl J Med; 1978 Oct; 299(16):852-7. PubMed ID: 692577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fraction of theophylline in sustained-release formulation which is absorbed from the large bowel.
    Sommers DK; Meyer EC; van Wyk M; Moncrieff J
    Eur J Clin Pharmacol; 1990; 38(2):171-3. PubMed ID: 1970960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gastrointestinal absorption of theophylline, especially with reference to retard preparations].
    Rameis H; Pötzi R; Kutscher R
    Z Gastroenterol; 1991 Jan; 29(1):1-5. PubMed ID: 2058222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of omeprazole-induced hypochlorhydria on absorption of theophylline from a sustained-release formulation.
    Sommers DK; van Wyk M; Snyman JR; Moncrieff J
    Eur J Clin Pharmacol; 1992; 43(2):141-3. PubMed ID: 1425870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.
    Hendeles L; Iafrate RP; Weinberger M
    Clin Pharmacokinet; 1984; 9(2):95-135. PubMed ID: 6370542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of gastric pH changes on pharmacokinetic of a sustained-release formulation of theophylline.
    Ferrari M; Olivieri M; Romito D; Biasin C; Barozzi E; Bassetti S
    Riv Eur Sci Med Farmacol; 1991; 13(5-6):269-74. PubMed ID: 1819857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intersubject variability of serum theophylline concentration after single dose of uncoated controlled release theophylline tablet administration in asthmatic patients.
    Raj NS; Guleria R; Misra A; Pande JN
    Indian J Chest Dis Allied Sci; 1997; 39(3):143-7. PubMed ID: 9357147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between rate and extent of absorption of oral theophylline from Uniphyl brand of slow-release theophylline and resulting serum concentrations during multiple dosing.
    Milavetz G; Vaughan LM; Weinberger MM; Harris JB; Mullenix TA
    J Allergy Clin Immunol; 1987 Nov; 80(5):723-9. PubMed ID: 3680816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system.
    González MA; Straughan AB
    Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
    González MA; Kisicki J; Straughn AB
    Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Release, absorption and elimination of theophylline from fast and slowly released oral formulations].
    Frömming KH; Schwabe L; Staib AH; Rietbrock N; Lassmann A; Molz KH; Schuppan D; Siebert-Weigel M; Voegele D
    Arzneimittelforschung; 1983; 33(3):446-52. PubMed ID: 6683521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Absorption profile and absolute bioavailability of a theophylline sustained-release preparation].
    Pabst G; Weber W; Barkworth MF; Müller M; Rehm KD
    Arzneimittelforschung; 1998 May; 48(5A):574-9. PubMed ID: 9676347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of enteral feedings on sustained-release theophylline absorption.
    Plezia PM; Thornley SM; Kramer TH; Armstrong EP
    Pharmacotherapy; 1990; 10(5):356-61. PubMed ID: 2122422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theophylline QID, TID, BID and now QD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24.
    Weinberger MM
    Pharmacotherapy; 1984; 4(4):181-98. PubMed ID: 6483637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative bioavailability and bioequivalence study of theophylline sustained release formulations.
    Vergin H; Mahr G; Winterhalter B; Wigand R
    Arzneimittelforschung; 2003; 53(9):635-9. PubMed ID: 14558437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur.
    Takagi K; Hasegawa T; Ogura Y; Yamaki K; Suzuki R; Satake T; Imaeda N; Mizukami Y
    Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):530-5. PubMed ID: 3429057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variations in absorption of theophylline from two sustained-release products.
    Ferrari M; Olivieri M; Barozzi E; Ramponi C
    Clin Ther; 1986; 8(6):646-54. PubMed ID: 3791362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative absorption of theophylline following multiple doses of a sustained-release formulation and an elixir in humans.
    Harrison LI; French IW; Mildon CA
    Clin Ther; 1982; 4(6):489-96. PubMed ID: 7093982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics of a theophylline sustained-release formulation after single and twice daily dosage].
    Fuchs WS; von Nieciecki A; Pabst G; Müller M; Dilger C; Gay S; Laicher A; Stanislaus F
    Arzneimittelforschung; 1998 May; 48(5A):589-92. PubMed ID: 9676350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.